Trade Vir Biotechnology VIR

Sell
 Buy

VirBiotechnology live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

News

Webhose 2026 Jan 29, 22:31

Chronic Hepatitis D Market Poised for Significant Growth During the Forecast Period (2025-2034) as Emerging Therapies Drive Optimism | DelveInsight

Vir Biotechnology Inc
Webhose 2026 Jan 26, 00:27

Vir Biotechnology (VIR) Is Up 24.8% After Strong SOLSTICE Combo Data In Hepatitis Delta Trial - Has The Bull Case Changed?

Vir Biotechnology Inc
Webhose 2026 Jan 23, 15:08

Vir Biotechnology (VIR) Is Up 19.4% After Strong Dual-Therapy Data in Hepatitis Delta Trial

Vir Biotechnology Inc
Webhose 2026 Jan 23, 12:15

Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Brokerages

Vir Biotechnology Inc
Webhose 2026 Jan 23, 09:40

A Look At Vir Biotechnology (VIR) Valuation After New SOLSTICE Trial Data And Pipeline Updates

Vir Biotechnology Inc
Webhose 2026 Jan 21, 20:33

Vir Biotechnology (NASDAQ:VIR) Shares Up 9.9% - Should You Buy?

Vir Biotechnology Inc
Webhose 2026 Jan 20, 19:00

Reviewing Vir Biotechnology (NASDAQ:VIR) and Creative Medical Technology (NASDAQ:CELZ) - Stock Observer

Vir Biotechnology Inc
Webhose 2026 Jan 13, 22:38

Vir Biotechnology (NASDAQ:VIR) Trading 7.3% Higher - What's Next?

Vir Biotechnology Inc
Webhose 2026 Jan 13, 14:38

Vir Biotechnology (NASDAQ:VIR) Trading Up 7.3% - Should You Buy? - Daily Political

Vir Biotechnology Inc
Webhose 2026 Jan 08, 02:26

Vir Biotechnology (NASDAQ:VIR) Director Sells $130,460.00 in Stock - Daily Political

Vir Biotechnology Inc
Webhose 2026 Jan 05, 21:10

Company Website: https://vir.bio SAN FRANCISCO -- (Busines

Vir Biotechnology Inc
Webhose 2026 Jan 05, 20:45

Vicki Sato Sells 22,000 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Vir Biotechnology Inc

VirBiotechnology news

number1 2025 Jul 11, 03:38

AI Podcast: Dollar Weakness and Investment Implications

number1 2025 Jul 11, 03:38

HSBC: Three 'Painful Trade' Risks Loom if Wall Street Gets It Wrong

number1 2025 Jul 11, 03:38

Turkey's $500 Billion Gold Hoard: Unlocking Economic Potential

number1 2025 Jul 11, 03:37

Brazil-US Tariffs: Trump's Intervention and Lula's Response

number1 2025 Jul 11, 00:00

AI Podcast: US & Israel's Disagreements on Iran and Gaza

Latest news

Show more
number1 2025 Oct 21, 00:00

Zelenskyy Expresses Doubts About Budapest as Venue for Ukraine Peace Talks

number1 2025 Oct 21, 00:00

Europe Rallies Behind Ukraine Amid Trump Pressure, Eyes Frozen Russian Assets

number1 2025 Oct 21, 00:00

US Government Shutdown: Economic Fallout and Political Impasse

number1 2025 Oct 21, 00:00

Gold Price Surge Fueled by Fed Rate Cut Expectations and Economic Uncertainty

number1 2025 Oct 19, 00:00

Global Market Overview: Precious Metals Surge Amidst Economic Uncertainty

number1 2025 Oct 18, 00:00

Japan LDP-Ishin Policy Talks: Paving the Way for a New Prime Minister?

number1 2025 Oct 18, 00:00

Israel Prepares to Reopen Rafah Crossing Amid Ceasefire Violation Claims

number1 2025 Oct 18, 00:00

Fed's Rate Cut Conundrum: An Outlook to 2026

Info

Spread

0.05

Spread (%)

0.8446 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Friday

14:31 - 20:59

Monday

14:31-20:59

Tuesday

14:31-20:59

Wednesday

14:31-20:59

Thursday

14:31-20:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

1072653952

Shares Outstanding

139125032

Earnings Date (Next)

0000-00-00

Div Yield

Ex-Dividend Date

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-3.62

Learn more about this instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments

latest_education_articles

Show more
Frances Wang 2025 Feb 17, 16:00

Pi network price prediction 2025: Will Pi Network price go up or down?

Stocks
Frances Wang 2025 Jan 21, 16:00

What is the XRP price prediction for 2025: Will XRP reach $1000?

Crypto
Frances Wang 2024 Dec 29, 16:00

What is the USD DXY index and how does the DXY reflect the dollar's value?

Indices
Trustpilot